Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Joshua Richter, MD
Sagar Lonial, MD, FACP
Noopur Raje, MD
Mastering the Sequence: CELMoDs Across Treatment Lines
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Safety First: Navigating CELMoD-Associated Toxicities
Why CELMoDs Matter in Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Real-World Ready: Practical Tips for Community Oncologists
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Data Dive: Clinical Evidence Behind CELMoDs
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD
John M. Kirkwood, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.